Coronavirus Clinical Trial
— CSSC-001Official title:
Convalescent Plasma to Stem Coronavirus: A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19
Verified date | April 2022 |
Source | Johns Hopkins University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Evaluate the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma versus control (SARS-CoV-2 non-immune plasma) in subjects exposed to Coronavirus disease (COVID-19) at day 28.
Status | Completed |
Enrollment | 180 |
Est. completion date | June 22, 2021 |
Est. primary completion date | April 22, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria 1. Subjects must be 18 years of age or older 2. Close contact exposure (as defined by CDC guidelines) to person with COVID-19 within 96 hours of randomization (and 120 hours of receipt of plasma) Exclusion Criteria 1. Receipt of any blood product in past 120 days. 2. Medical, psychiatric,cognitive illness or recreational drug/alcohol use that in the opinion of the principal investigator, would affect subject safety and/or compliance. 3. Symptoms consistent with COVID-19 infection (fevers, acute onset cough, shortness of breath) at time of screening. 4. Laboratory evidence of COVID-19 infection at time of screening. 5. History or known laboratory evidence of previous COVID-19 infection. 6. History of prior reactions to transfusion blood products. 7. Inability to complete therapy with the study product within 24 hours after randomization. |
Country | Name | City | State |
---|---|---|---|
United States | University of New Mexico Health Sciences Center | Albuquerque | New Mexico |
United States | Anne Arundel Medical Center | Annapolis | Maryland |
United States | The Johns Hopkins University | Baltimore | Maryland |
United States | University of Alabama at Birmingham | Birmingham | Alabama |
United States | University of Cincinnati Medical Center | Cincinnati | Ohio |
United States | University of Miami | Coral Gables | Florida |
United States | Western Connecticut Health Network, Danbury Hospital | Danbury | Connecticut |
United States | Wayne State University | Detroit | Michigan |
United States | NorthShore University HealthSystem | Evanston | Illinois |
United States | Center for American Indian Health - Gallup Office | Gallup | New Mexico |
United States | Baylor College of Medicine | Houston | Texas |
United States | University of Texas Health Science Center at Houston | Houston | Texas |
United States | University of California, San Diego | La Jolla | California |
United States | University of California, Los Angeles | Los Angeles | California |
United States | University of Miami Clinical Translational Research Site | Miami | Florida |
United States | Western Connecticut Health Netowrk, Norwalk Hospital | Norwalk | Connecticut |
United States | University of California, Irvine Health | Orange | California |
United States | Vassar Brothers Medical Center | Poughkeepsie | New York |
United States | Lifespan/BrownUniversity (Rhode Island Hospital) | Providence | Rhode Island |
United States | University of Rochester | Rochester | New York |
United States | The University of Utah | Salt Lake City | Utah |
United States | Center for American Indian Health - Shiprock Office | Shiprock | New Mexico |
United States | MedStar Georgetown University Hospital | Washington | District of Columbia |
United States | Center for American Indian Health - Whiteriver Office | Whiteriver | Arizona |
United States | University of Massachusetts Worcester | Worcester | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Efficacy of Treatment at Day 28 as Assessed by Number of Participants Who Develop SARS-Cov-2 Infection | Comparison of proportions of cumulative incidence of development of SARS-Cov-2 infection (symptoms compatible with infection and/or + molecular testing) regardless of disease severity, following high-titer Anti- SARS-CoV-2 plasma versus control (SARS-CoV-2 non-immune plasma) in subjects exposed to COVID-19. | Day 28 | |
Primary | Safety of Treatment With High-titer Anti- SARS-CoV-2 Plasma Versus Control as Assessed by Number of Participants With "Serious Adverse Events" | Number of participants with serious adverse events categorized as either severe infusion reactions or Acute Respiratory Distress Syndrome during the study period. | Up to Day 28 | |
Primary | Safety of Treatment With High-titer Anti- SARS-CoV-2 Plasma Versus Control as Assessed by Cumulative Incidence of Grade 3 and 4 Adverse Events | Cumulative incidence of grade 3 and 4 adverse events during the study period evaluated as events per 100 person-years will be used to assess safety of the intervention. | Up to Day 28 | |
Secondary | Number of Participants With Severe Disease | Number of participants with severe disease between the anti-SARS-CoV-2 convalescent plasma and control groups. Severity of disease will be measured using the number of participants with any of the disease severity categories below:
Death Requiring mechanical ventilation and/or in ICU non-ICU hospitalization, requiring supplemental oxygen non-ICU hospitalization, not requiring supplemental oxygen |
Up to 28 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05065827 -
Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
|
||
Recruiting |
NCT05359770 -
Association of Inspiratory Muscle Training With HD-tDCS for Assistance to Patients With Long Covid-19
|
N/A | |
Completed |
NCT04515147 -
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
|
Phase 2 | |
Not yet recruiting |
NCT06025812 -
Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)
|
N/A | |
Recruiting |
NCT05289115 -
Protocol for Assistance to Patients With Long Covid-19 Undergoing Treatment With HD-tDCS
|
N/A | |
Completed |
NCT04953078 -
A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19
|
Phase 1 | |
Completed |
NCT04779138 -
Increasing Vaccine Uptake in Underresourced Public Housing Areas
|
N/A | |
Not yet recruiting |
NCT05868239 -
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
|
N/A | |
Completed |
NCT04818164 -
Prone Position Improves End-Expiratory Lung Volumes in COVID-19 Acute Respiratory Distress Syndrome
|
||
Completed |
NCT04690413 -
NOWDx Test for the Detection of Antibodies to COVID-19
|
N/A | |
Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
Completed |
NCT04572399 -
UVA Light Device to Treat COVID-19
|
N/A | |
Recruiting |
NCT04610567 -
Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04772170 -
Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies
|
||
Recruiting |
NCT04581954 -
Inflammatory Signal Inhibitors for COVID-19 (MATIS)
|
Phase 1/Phase 2 | |
Completed |
NCT04405934 -
COG-UK Project Hospital-Onset COVID-19 Infections Study
|
N/A | |
Enrolling by invitation |
NCT04484025 -
SPI-1005 Treatment in Moderate COVID-19 Patients
|
Phase 2 | |
Completed |
NCT05572840 -
Wear Your Mask, Wash Your Hands, Don't Get COVID-19
|
N/A | |
Withdrawn |
NCT04838847 -
A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
|
Phase 3 | |
Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 |